Evidence map›Paper›PMID 35276990›Full record

ArticleNutrients2022

Introduction of Heated Cow's Milk Protein in Challenge-Proven Cow's Milk Allergic Children: The iAGE Study.

Nicolette W de Jong, Marloes E van Splunter, Joyce A M Emons, Kasper A Hettinga, Roy Gerth van Wijk, Harry J Wichers, Huub F J Savelkoul, Aline B Sprikkelman, R J Joost van Neerven, Liu Liu and 15 more

Abstract read
In one paragraph

Article in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Casein sIgE as the most accurate predictor for heated milk tolerance in Finnish children.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025
    Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Nicolette W de JongDepartment of Internal Medicine, Section of Allergology & Clinical Immunology, Erasmus MC, University Medical Centre Rotterdam, 3015GD Rotterdam, The Netherlands.
Marloes E van SplunterDepartment of Internal Medicine, Section of Allergology & Clinical Immunology, Erasmus MC, University Medical Centre Rotterdam, 3015GD Rotterdam, The Netherlands.
Joyce A M EmonsDepertment of Peadiatric Allergology, Sophia Children Hospital, Erasmus MC, University Medical Centre Rotterdam, 3015GD Rotterdam, The Netherlands.
Kasper A HettingaFood Quality & Design Group, Wageningen University & Research Centre, 6708PB Wageningen, The Netherlands.ORCID 0000-0002-9017-4447
Roy Gerth van WijkDepartment of Internal Medicine, Section of Allergology & Clinical Immunology, Erasmus MC, University Medical Centre Rotterdam, 3015GD Rotterdam, The Netherlands.
Harry J WichersFood Quality & Design Group, Wageningen University & Research Centre, 6708PB Wageningen, The Netherlands.ORCID 0000-0002-8030-7090
Huub F J SavelkoulCell Biology & Immunology Group, Wageningen University & Research Centre, 6708PB Wageningen, The Netherlands.ORCID 0000-0001-6236-7092
Aline B SprikkelmanDepartment of Peadiatric Pulmonology & Allergology, UMCG, University Medical Center Groningen, 9713GZ Groningen, The Netherlands.
R J Joost van NeervenCell Biology & Immunology Group, Wageningen University & Research Centre, 6708PB Wageningen, The Netherlands.ORCID 0000-0002-3991-5297
Liu LiuDepartment of Rheumatoloy, Leiden University, 2311BD Leiden, The Netherlands.
Gerbrich van der MeulenDepartment of Peadiatrics, Martini Hospital, 9728NT Groningen, The Netherlands.
Irene HerpertzPaediatric Allegology Center, VieCuri Medisch Centrum, 5912BL Venlo, The Netherlands.
Yvonne C M DuijvestijnDepartment of Peadiatrics, Noordwest Ziekenhuisgroep, 1815JD Alkmaar, The Netherlands.
Mijke BreukelsDeparment of Peadiatrics, Elkerliek, 5707HA Helmond, The Netherlands.
Marianne I BrouwerDepartment of Peadiatrics, Canisius Wilhelmina Ziekenhuis, 6532SZ Nijmegen, The Netherlands.
Jaap SchilperoordDepartment of Peadiatrics, OLVG Hospital, 1091AC Amsterdam, The Netherlands.
Olga van DoornDepartment of Peadiatrics, OLVG Hospital, 1091AC Amsterdam, The Netherlands.
Berber Vlieg-BoerstraDepartment of Peadiatrics, OLVG Hospital, 1091AC Amsterdam, The Netherlands.ORCID 0000-0001-7962-5406
Jochum van den BergDepartment of Peadiatrics, Zuyderland MC, 6419PC Heerlen, The Netherlands.
Linette PellisAusnutria B.V., 8025BM Zwolle, The Netherlands.
Severina TerlouwDepartment of Internal Medicine, Section of Allergology & Clinical Immunology, Erasmus MC, University Medical Centre Rotterdam, 3015GD Rotterdam, The Netherlands.ORCID 0000-0003-1724-3626
Astrid I HendriksDepertment of Peadiatric Allergology, Sophia Children Hospital, Erasmus MC, University Medical Centre Rotterdam, 3015GD Rotterdam, The Netherlands.
Marco W J SchreursDepartment of Immunology, Erasmus MC, University Medical Centre Rotterdam, 3015GD Rotterdam, The Netherlands.
Frank E van BovenDepartment of Internal Medicine, Section of Allergology & Clinical Immunology, Erasmus MC, University Medical Centre Rotterdam, 3015GD Rotterdam, The Netherlands.
Nicolette J T ArendsDepertment of Peadiatric Allergology, Sophia Children Hospital, Erasmus MC, University Medical Centre Rotterdam, 3015GD Rotterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The introduction of baked milk products in cow's milk (CM) allergic children has previously been shown to accelerate induction tolerance in a selected group of children. However, there is no standardized baked milk product on the market. Recently, a new standardized, heated and glycated cow's milk protein (HP) product was developed. The aim of this study was to measure safety and tolerability of a new, well characterized heated CM protein (HP) product in cow's milk allergic (CMA) children between the age of 3 and 36 months. The children were recruited from seven clinics throughout The Netherlands. The HP product was introduced in six incremental doses under clinical supervision. Symptoms were registered after introduction of the HP product. Several questionnaires were filled out by parents of the children. Skin prick tests were performed with CM and HP product, sIgE to CM and α-lactalbumin (Bos d4), β-lactoglobulin (Bos d5), serum albumin (Bos d 6), lactoferrin (Bos d7) and casein (Bos d8). Whereas 72% percent (18 out of 25) of the children tolerated the HP product, seven children experienced adverse events. Risk factors for intolerance to the HP product were higher skin prick test (SPT) histamine equivalent index (HEP) results with CM and the HP product, higher specific IgE levels against Bos d4 and Bos d8 levels and Bos d5 levels. In conclusion, the HP product was tolerated by 72% of the CM allergic children. Outcomes of SPT with CM and the HP product, as well as values of sIgE against caseins, α-lactalbumin, and β-lactoglobulin may predict the tolerability of the HP product. Larger studies are needed to confirm these conclusions.

Indexed as

MilkMilk HypersensitivityAllergensAnimalsCaseinsCattleFemaleImmunoglobulin EAllergensCaseinsImmunoglobulin Eallergybaked milkcow’s milktolerance

Identifiers

PMID35276990
PMCPMC8838309

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.